Treatments with nirogacestat

A method for treating desmoid tumor in a patient in need thereof, where (i) the patient previously was treated for desmoid tumor with 150 mg (free base equivalent dose) of nirogacestat or a pharmaceutically acceptable salt thereof orally twice daily and, during such prior treatment, experienced an alanine transaminase (ALT) or aspartate aminotransferase (AST) of 3 to 5 times upper limit of normal (ULN) and (ii) the ALT, AST, or both are resolved to less than 3 times ULN or baseline, the method comprising orally administering to the patient 100 mg (free base equivalent dose) of nirogacestat or a pharmaceutically acceptable salt thereof twice daily.

(canceled)

A method for treating desmoid tumor in a patient in need thereof, where (i) the patient previously was treated for desmoid tumor with 150 mg (free base equivalent dose) of nirogacestat or a pharmaceutically acceptable salt thereof orally twice daily and, during such prior treatment, experienced Grade 3 or 4 hypokalemia despite maximal replacement therapy and (ii) the hypokalemia is resolved to no higher than a Grade 1 hypokalemia or baseline, the method comprising orally administering to the patient 100 mg (free base equivalent dose) of nirogacestat or a pharmaceutically acceptable salt thereof twice daily.

53-54. (canceled)

A method for treating desmoid tumor in a patient in need thereof, where (i) the patient previously was treated for desmoid tumor with 150 mg (free base equivalent dose) of nirogacestat or a pharmaceutically acceptable salt thereof orally twice daily and, during such prior treatment, experienced Grade 3 or 4 hypophosphatemia despite maximal replacement therapy and (ii) the hypophosphatemia is resolved to no higher than a Grade 1 hypophosphatemia or baseline, the method comprising orally administering to the patient 100 mg (free base equivalent dose) of nirogacestat or a pharmaceutically acceptable salt thereof twice daily.

83-88. (canceled)